StockWatch
·

Meghmani Organics Ltd Q2 FY27 Results

MOLQ2 FY27 Results
Filing
Result:Steady· Market: Flat#Turnaround#Base effect#Margin squeeze

Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue666.9222.9%15.5%
Total Income686.9923.8%13.6%
Expenditure639.0431.0%10.4%
PBT47.9528.4%83.8%
Net Profit33.8829.7%193.3%
OPM10.97%7.07pp1.95pp
NPM4.93%3.76pp3.02pp
EPS1.3330.0%195.6%
View full financials

Consolidated PAT's 193% YoY jump is mostly a low-base turnaround in Pigments/TiO2 (post anti-dumping-duty restart), while the core Agrochemicals segment (~75% of revenue) saw profit fall 33% YoY and margins compress sharply as input costs outran pricing, so adjusted core profitability is deteriorating even as headline numbers look strong.

MOL · Q2 FY27 · THE VERDICT

Growth Masking the Real Story: Margins Halved, Receivables Spiking

Revenue grew 15.5% and profit hit targets, but Crop Protection's EBITDA margin collapsed from 15–17% guidance to 11%. Trade receivables jumped to ₹220 Cr and TiO2 operations are now suspended indefinitely. The headline beat obscures real operational stress.

07 Nov 2026 · 6 min read
Consolidated Revenue

₹666.9 Cr

+15.5% YoY, +22.9% QoQ

Net Profit

₹33.9 Cr

+193% YoY, −29.7% QoQ

EBITDA Margin

11%

Crop Protection guidance 15–17%, delivered 11%

Trade Receivables

₹220 Cr

DSO extended to 110–115 days

Meghmani Organics delivered on the headline: ₹666.9 Cr revenue and ₹33.9 Cr profit hit consolidated targets exactly. But the quarter masks a deterioration in operational quality. Crop Protection, which is 75% of revenue at ₹496 Cr, has an EBITDA margin of 11% — a 4–6 percentage point miss against the company's own 15–17% guidance. Raw material costs, particularly sulfuric acid, have spiked 7–8 times normal levels. Logistics costs have surged. Trade receivables jumped to ₹220 Cr with payment cycles extended from 100–110 days to 110–115 days, signaling that the company is offering credit to push sales in a softening market. And the TiO2 segment, once a profit contributor, is now suspended indefinitely because restarting is commercially unviable at current raw material costs.

The profit number, while impressive on paper at +193% YoY, sits on a very weak base: Q2 FY26 earned just ₹11.8 Cr. More concerning, Q2 profit fell 29.7% quarter-over-quarter from Q1 FY27, implying that the first quarter was materially stronger on margin. Half-year revenue of ₹1,181 Cr is only +3% YoY — a pace that Q2's +15.5% growth cannot sustain. Q1 must have been near-flat or negative, which raises questions about the strength of underlying demand.

Management's claims versus what holds up

Earnings call assertions graded against the numbers

Consolidated revenue ₹666 Cr, up 16% YoY

Delivered ₹666.9 Cr, +15.5% YoY

Supported

Consolidated net profit ₹33.9 Cr, up 193% YoY

Delivered ₹33.9 Cr PAT, +193.3% YoY

Supported (but on small base)

Crop Protection 15–17% EBITDA margin target maintained

Segment delivered 11% EBITDA (₹54 Cr on ₹496 Cr revenue)

Overstated — margin miss of 4–6 pts

Logistics cost rising gradually, normalizing

Management acknowledges 'sharp increase'; normalization timeline vague; DSO extended

Contradicted — costs not normalizing yet

EBITDA grew 40% YoY to ₹73 Cr

Implied EBITDA ~₹73–74 Cr; growth rate aligns

Supported on the growth rate

What changed on this call

This quarter brings three material shifts. First, TiO2 is now suspended indefinitely. The company had been operating a titanium dioxide segment; it was suspended in response to a re-imposed antidumping duty (October 2026) combined with sulfuric acid costs at 7–8 times normal levels, making restart 'not commercially viable' in the foreseeable future. Management has offered no timeline for a restart — it is exploring strategic options but gave no specifics. For a prior profit contributor, this is a structural impairment that the company has not yet written down.

Second, working capital has deteriorated. Trade receivables jumped to ₹220 Cr. Management extended the payment cycle from 100–110 days to 110–115 days to support customers in a 'challenging market.' This is not merely a seasonal working capital swing; it signals either credit risk (customers cannot pay on the old terms) or demand softness (the company must offer credit to move volume). The risk of bad debts rising is real, though not yet quantified.

Third, Crop Nutrition conviction has upgraded. Management reaffirmed very optimistic long-term outlook and claimed that new Nano products (Nano DAP, Nano NPK, Nano Zinc) will contribute 20–22% of consolidated EBITDA over the next 3 years. Prior guidance was ₹100 Cr revenue over 2–3 years, which translates to ~₹33 Cr annually. The new EBITDA target is materially more ambitious. However, execution risk is high: Nano urea (a competing product) has struggled with adoption. Management is confident Nano DAP will fare better, but this is early-stage and unproven at scale.

The bull case and the bear case

The bull–bear ledger
  • Revenue momentum solid at 15.5% YoY

  • Consolidated numbers (₹666.9 Cr, ₹33.9 Cr) hit exactly

  • Debt repayment on track; leverage low

  • Long-term product pipeline to 2031; 70+ countries

  • Crop Protection margin missed 15–17% guidance by 4–6 pts

  • Raw material (sulfuric acid) costs 7–8x normal; recovery timeline vague

  • Trade receivables ₹220 Cr; DSO extended; signals market stress

  • TiO2 operations suspended indefinitely

  • QoQ profit fell 29.7%; HY growth only 3% YoY vs Q2's 15.5%

  • Crop Nutrition very early stage; adoption risk on Nano products

Risks ranked by how much they should concern a holder

Key risks to the investment thesis, ordered by severity

Crop Protection margin recovery uncertain

High

Guided 15–17% EBITDA; delivered 11%. Raw materials remain elevated (7–8x normal) with no quantified timeline for normalization. If cost pressure persists into Q3 and Q4, the recovery won't happen this fiscal year. The company's credibility on near-term execution is now in question.

Trade receivables spike and DSO extension

High

₹220 Cr receivables with payment cycles at 110–115 days (extended from 100–110) is a red flag. Management attributed this to credit extension in a challenging market. If receivables don't normalize and bad debts rise, working capital will deteriorate further, pressuring cash flow and debt paydown.

TiO2 segment suspended indefinitely

High

A former profit contributor is now a dead asset. Sulfuric acid costs remain uneconomic and there is a 5-year antidumping duty (Oct 2026 onwards). No restart timeline given. The company will likely have to write down or divest the asset, crystallizing a loss. This is unquantified and hanging over the stock.

Half-year revenue growth deceleration

Medium

HY revenue ₹1,181 Cr is only +3% YoY, but Q2 was +15.5%. This implies Q1 was near-flat or negative. Sequential weakness suggests Q2's growth is not sustainable. Next quarter, if Q3 slows again, the long-term growth thesis comes into question.

Crop Nutrition execution and adoption risk

Medium

Management is very bullish on Nano products contributing 20–22% of consolidated EBITDA over 3 years. But Nano urea (a competing product) has struggled with adoption. Nano DAP is in early-stage field trials. Execution risk is high; the ramp may take longer than expected or fail entirely, eroding the long-term growth case.

Geopolitical and tariff headwinds

Medium

US tariffs impact pigment exports; Europe is a weak market. Re-imposed antidumping duty on TiO2 has already suspended that segment. Further trade friction could pressurize margins across segments.

How the street sees it

The stock is trading at ₹54.27, down 64% from its all-time high of ₹152.5 but up 49% off its 52-week low of ₹36.5. It sits below its 20-day moving average (₹55.52) and well below its 50-day (₹58.9), though above its 200-day (₹53.43). RSI is 44.5, indicating neutral momentum with a tilt towards oversold. Volume has been normal; no panic liquidation. The post-result price action will clarify whether the market is pricing in the margin miss or overlooking it in favor of long-term growth.

On ownership, FII holdings have declined from 1.34% in FY26 Q4 to 0.91% in FY27 Q1 — a 43 basis point withdrawal over one quarter. DII presence is negligible at 0.00%. Promoter ownership remains stable at ~49%, indicating no insider selling. Recent bulk/block deals (last 6 months) show institutional flow but no red flags: NK Securities and QE Securities bought and sold in the ₹57.70–57.82 range in matched transactions, suggesting neutral positioning. No promoter-linked selling near the all-time high. However, the FII withdrawal during a quarter of announced guidance miss is a signal that foreign institutions are not confident in the near-term recovery narrative.

What to watch next
  • 1 · Q3 FY27 (Dec 2026 results): Input cost and logistics normalization

    The next quarter will clarify whether sulfuric acid costs and logistics premiums are normalizing. If Crop Protection EBITDA margin improves even modestly (to 12–13%), the recovery narrative gains credibility. If it stays at 11% or worsens, the company's cost management claims are hollow and the margin guidance reset is necessary.

  • 2 · Trade receivables and DSO trajectory

    Watch whether receivables normalize back towards the 100–110 day cycle or remain elevated at 110–115 days. If they stay high or worsen into Q3, it confirms persistent market softness and rising bad-debt risk. If they fall sharply, it confirms the credit extension was temporary and demand is stabilizing.

  • 3 · Crop Nutrition revenue visibility

    By H2 FY27 or Q1 FY28, Nano DAP and Nano NPK should show measurable revenue contribution (even if immaterial to consolidated results). Field trials are said to be positive, but until actual sales appear in the income statement, the 20–22% EBITDA contribution target is speculation. Early signs of customer offtake would validate the long-term thesis.

Meghmani Organics is in a transition quarter, not a growth inflection. The headline — revenue up 15.5%, profit up 193% — masks a softer operational reality: margins halved, working capital extended, and a segment suspended. Management's long-term conviction (double-digit growth, 13–14% consolidated EBITDA margin, Crop Nutrition scale) is credible on paper, supported by a product pipeline and debt discipline. But near-term execution has stumbled. The company will earn conviction only if it proves cost normalization and Crop Nutrition revenue materialize by year-end.

The number to track from here is the Crop Protection EBITDA margin in Q3. If it recovers towards 12–13%, the quarter was a blip and the hold case strengthens. If it remains at 11%, management's guidance is not worth the paper it is written on, and downside risk widens.

Informational and educational content only. Not investment advice.